Regulus Historical Balance Sheet

RGLS Stock

USD 1.61 0.03 1.83%

Trend analysis of Regulus Therapeutics balance sheet accounts such as Other Liabilities of 1 M, Accounts Payable of 193.8 K, Cash of 35.1 M or Other Assets of 0.86 provides information on Regulus Therapeutics' total assets, liabilities, and equity, which is the actual value of Regulus Therapeutics to its prevalent stockholders. By breaking down trends over time using Regulus Therapeutics balance sheet statements, investors will see what precisely the company owns and what it owes to creditors or other parties at the end of each accounting year.

Cash Flow Balance Sheet Income Statement

Yuan Drop

Covid

Financial Statement Analysis is much more than just reviewing and examining Regulus Therapeutics latest accounting reports to predict its past. Macroaxis encourages investors to analyze financial statements over time for various trends across multiple indicators and accounts to determine whether Regulus Therapeutics is a good buy for the upcoming year.

Regulus Therapeutics Inventory

3.16 Million

Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Regulus Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in bureau of economic analysis.

For more information on how to buy Regulus Stock please use our How to Invest in Regulus Therapeutics guide.

About Regulus Balance Sheet Analysis

Balance Sheet is a snapshot of the financial position of Regulus Therapeutics at a specified time, usually calculated after every quarter, six months, or one year. Regulus Therapeutics Balance Sheet has two main parts: assets and liabilities. Liabilities are the debts or obligations of Regulus Therapeutics and are divided into current liabilities and long term liabilities. An asset, on the other hand, is anything of value that can be converted into cash and which Regulus currently owns. An asset can also be divided into two categories, current and non-current.

Regulus Therapeutics Balance Sheet Chart

At this time, Regulus Therapeutics' Non Current Assets Total are comparatively stable compared to the past year. Non Currrent Assets Other is likely to gain to about 3.6 M in 2024, whereas Other Liabilities is likely to drop slightly above 1 M in 2024.

Total Assets Total Current Liabilities Other Liab Accounts Payable

Add Fundamental

Total Assets

Total assets refers to the total amount of Regulus Therapeutics assets owned. Assets are items that have some economic value and are expended over time to create a benefit for the owner. These assets are usually recorded in Regulus Therapeutics books under different categories such as cash, marketable securities, accounts receivable,prepaid expenses, inventory, fixed assets, intangible assets, other assets, marketable securities, accounts receivable, prepaid expenses and others. The total value of all owned resources that are expected to provide future economic benefits to the business, including cash, investments, accounts receivable, inventory, property, plant, equipment, and intangible assets.

Total Current Liabilities

Total Current Liabilities is an item on Regulus Therapeutics balance sheet that include short term debt, accounts payable, accrued salaries payable, payroll taxes payable, accrued liabilities and other debts. Total Current Liabilities of Regulus Therapeutics are important to investors because some useful performance ratios such as Current Ratio and Quick Ratio require Total Current Liabilities to be accurate. The total amount of liabilities that a company is expected to pay within one year, including debts, accounts payable, and other short-term financial obligations.

Accounts Payable

An accounting item on the balance sheet that represents Regulus Therapeutics obligation to pay off a short-term debt to its creditors. The accounts payable entry is usually reported under current liabilities. If accounts payable of Regulus Therapeutics are not paid within the agreed terms, the payables are considered to be in default, which may trigger a penalty or interest payment, or the revocation of additional credit from the supplier. Accounts payable may also be considered a source of cash, since they represent funds being borrowed from suppliers. Given these cash flow considerations, suppliers have a natural inclination to push for shorter payment terms, while creditors want to lengthen the payment terms. The amount a company owes to suppliers or vendors for products or services received but not yet paid for. It represents the company's short-term liabilities.

Most accounts from Regulus Therapeutics' balance sheet are interrelated and interconnected. However, analyzing balance sheet accounts one by one will only give a small insight into Regulus Therapeutics current financial condition. On the other hand, looking into the entire matrix of balance sheet accounts, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Regulus Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in bureau of economic analysis.

For more information on how to buy Regulus Stock please use our How to Invest in Regulus Therapeutics guide.At this time, Regulus Therapeutics' Non Current Assets Total are comparatively stable compared to the past year. Non Currrent Assets Other is likely to gain to about 3.6 M in 2024, whereas Other Liabilities is likely to drop slightly above 1 M in 2024.

	2023	2024 (projected)
Accounts Payable	204K	193.8K
Other Liabilities	1.1M	1.0M

Accounts Payable Other Liab

Regulus Therapeutics balance sheet Correlations

	Total Assets	Other Current Liab	Total Current Liabilities	Total Stockholder Equity	Other Liab	Accounts Payable	Cash	Other Assets	Long Term Debt	Common Stock Shares Outstanding	Short Term Investments	Other Current Assets	Total Liab	Preferred Stock Total Equity	Intangible Assets	Property Plant Equipment	Short Long Term Debt Total	Property Plant And Equipment Net	Current Deferred Revenue	Net Debt	Retained Earnings	Non Current Assets Total	Non Currrent Assets Other	Cash And Short Term Investments	Non Current Liabilities Total	Other Stockholder Equity
Total Assets		-0.55	-0.32	0.9	0.07	0.36	0.64	0.78	-0.02	-0.4	0.95	0.59	0.1	-0.23	0.71	0.23	0.66	0.23	0.07	-0.55	0.55	0.4	-0.12	0.97	0.13	-0.29
Other Current Liab	-0.55		0.23	-0.44	0.15	0.05	0.07	-0.78	0.24	0.15	-0.5	0.04	-0.17	0.15	-0.29	0.14	-0.36	0.13	-0.07	-0.13	-0.24	-0.03	-0.15	-0.61	-0.1	0.1
Total Current Liabilities	-0.32	0.23		-0.4	0.13	0.5	-0.48	-0.15	-0.21	-0.23	-0.25	-0.18	0.21	-0.02	-0.02	0.49	0.3	0.48	-0.12	0.53	-0.18	0.43	-0.2	-0.38	-0.13	0.08
Total Stockholder Equity	0.9	-0.44	-0.4		-0.27	0.23	0.72	0.66	-0.2	-0.15	0.78	0.62	-0.33	-0.53	0.4	0.09	0.48	0.09	-0.24	-0.68	0.21	0.22	0.07	0.88	-0.25	0.08
Other Liab	0.07	0.15	0.13	-0.27		0.15	-0.16	-0.02	0.56	-0.55	0.24	-0.13	0.81	0.75	0.67	0.23	0.2	0.22	0.86	0.24	0.79	0.26	-0.51	0.07	0.88	-0.88
Accounts Payable	0.36	0.05	0.5	0.23	0.15		0.19	0.32	0.06	-0.46	0.41	0.48	0.28	-0.16	0.45	0.87	0.74	0.87	-0.25	-0.07	0.12	0.89	-0.32	0.28	0.04	0.0
Cash	0.64	0.07	-0.48	0.72	-0.16	0.19		0.28	0.16	-0.21	0.58	0.73	-0.25	-0.34	0.37	0.15	0.34	0.15	-0.16	-0.98	0.25	0.22	-0.16	0.61	-0.15	-0.03
Other Assets	0.78	-0.78	-0.15	0.66	-0.02	0.32	0.28		-0.23	-0.39	0.78	0.2	0.19	-0.18	0.55	0.2	0.69	0.21	0.01	-0.17	0.4	0.39	-0.04	0.8	0.14	-0.18
Long Term Debt	-0.02	0.24	-0.21	-0.2	0.56	0.06	0.16	-0.23		-0.21	0.04	-0.05	0.41	0.27	0.34	0.24	-0.07	0.23	0.46	-0.1	0.41	0.22	-0.27	-0.02	0.49	-0.48
Common Stock Shares Outstanding	-0.4	0.15	-0.23	-0.15	-0.55	-0.46	-0.21	-0.39	-0.21		-0.53	-0.24	-0.63	-0.26	-0.78	-0.32	-0.75	-0.3	-0.52	0.11	-0.72	-0.41	0.88	-0.45	-0.5	0.58
Short Term Investments	0.95	-0.5	-0.25	0.78	0.24	0.41	0.58	0.78	0.04	-0.53		0.57	0.29	-0.06	0.84	0.28	0.74	0.28	0.22	-0.49	0.69	0.46	-0.18	0.94	0.29	-0.44
Other Current Assets	0.59	0.04	-0.18	0.62	-0.13	0.48	0.73	0.2	-0.05	-0.24	0.57		-0.12	-0.24	0.39	0.4	0.51	0.41	-0.26	-0.72	0.16	0.44	-0.16	0.51	-0.13	0.05
Total Liab	0.1	-0.17	0.21	-0.33	0.81	0.28	-0.25	0.19	0.41	-0.63	0.29	-0.12		0.73	0.68	0.3	0.41	0.3	0.72	0.34	0.74	0.36	-0.51	0.13	0.87	-0.81
Preferred Stock Total Equity	-0.23	0.15	-0.02	-0.53	0.75	-0.16	-0.34	-0.18	0.27	-0.26	-0.06	-0.24	0.73		0.29	-0.14	-0.09	-0.15	0.73	0.36	0.56	-0.14	-0.3	-0.22	0.88	-0.75
Intangible Assets	0.71	-0.29	-0.02	0.4	0.67	0.45	0.37	0.55	0.34	-0.78	0.84	0.39	0.68	0.29		0.4	0.74	0.39	0.59	-0.26	0.92	0.54	-0.52	0.71	0.63	-0.77
Property Plant Equipment	0.23	0.14	0.49	0.09	0.23	0.87	0.15	0.2	0.24	-0.32	0.28	0.4	0.3	-0.14	0.4		0.6	1.0	-0.19	-0.05	0.08	0.98	-0.23	0.13	0.06	-0.03
Short Long Term Debt Total	0.66	-0.36	0.3	0.48	0.2	0.74	0.34	0.69	-0.07	-0.75	0.74	0.51	0.41	-0.09	0.74	0.6		0.6	0.02	-0.21	0.48	0.72	-0.47	0.65	0.18	-0.26
Property Plant And Equipment Net	0.23	0.13	0.48	0.09	0.22	0.87	0.15	0.21	0.23	-0.3	0.28	0.41	0.3	-0.15	0.39	1.0	0.6		-0.21	-0.05	0.07	0.98	-0.22	0.14	0.04	-0.01
Current Deferred Revenue	0.07	-0.07	-0.12	-0.24	0.86	-0.25	-0.16	0.01	0.46	-0.52	0.22	-0.26	0.72	0.73	0.59	-0.19	0.02	-0.21		0.19	0.83	-0.13	-0.48	0.13	0.83	-0.91
Net Debt	-0.55	-0.13	0.53	-0.68	0.24	-0.07	-0.98	-0.17	-0.1	0.11	-0.49	-0.72	0.34	0.36	-0.26	-0.05	-0.21	-0.05	0.19		-0.16	-0.1	0.11	-0.53	0.23	-0.04
Retained Earnings	0.55	-0.24	-0.18	0.21	0.79	0.12	0.25	0.4	0.41	-0.72	0.69	0.16	0.74	0.56	0.92	0.08	0.48	0.07	0.83	-0.16		0.22	-0.52	0.58	0.81	-0.93
Non Current Assets Total	0.4	-0.03	0.43	0.22	0.26	0.89	0.22	0.39	0.22	-0.41	0.46	0.44	0.36	-0.14	0.54	0.98	0.72	0.98	-0.13	-0.1	0.22		-0.25	0.31	0.12	-0.13
Non Currrent Assets Other	-0.12	-0.15	-0.2	0.07	-0.51	-0.32	-0.16	-0.04	-0.27	0.88	-0.18	-0.16	-0.51	-0.3	-0.52	-0.23	-0.47	-0.22	-0.48	0.11	-0.52	-0.25		-0.17	-0.42	0.44
Cash And Short Term Investments	0.97	-0.61	-0.38	0.88	0.07	0.28	0.61	0.8	-0.02	-0.45	0.94	0.51	0.13	-0.22	0.71	0.13	0.65	0.14	0.13	-0.53	0.58	0.31	-0.17		0.15	-0.29
Non Current Liabilities Total	0.13	-0.1	-0.13	-0.25	0.88	0.04	-0.15	0.14	0.49	-0.5	0.29	-0.13	0.87	0.88	0.63	0.06	0.18	0.04	0.83	0.23	0.81	0.12	-0.42	0.15		-0.9
Other Stockholder Equity	-0.29	0.1	0.08	0.08	-0.88	0.0	-0.03	-0.18	-0.48	0.58	-0.44	0.05	-0.81	-0.75	-0.77	-0.03	-0.26	-0.01	-0.91	-0.04	-0.93	-0.13	0.44	-0.29	-0.9

Click cells to compare fundamentals

Regulus Therapeutics Account Relationship Matchups

Regulus Therapeutics balance sheet Accounts

	2019	2020	2021	2022	2023	2024 (projected)
Total Assets	42.1M	37.6M	68.5M	46.7M	30.8M	61.4M
Other Current Liab	5.6M	6.4M	4.9M	7.0M	7.0M	4.8M
Total Current Liabilities	21.6M	11.6M	5.2M	11.7M	8.5M	15.5M
Total Stockholder Equity	20.0M	26.0M	55.0M	33.3M	21.2M	35.4M
Other Liab	10.0M	7.1M	468K	1.2M	1.1M	1.0M
Accounts Payable	1.3M	535K	285K	175K	204K	193.8K
Cash	34.1M	31.1M	60.4M	24.2M	23.8M	35.1M
Other Assets	0.0	24K	291K	1.0	0.9	0.86
Common Stock Shares Outstanding	1.7M	3.5M	8.6M	15.3M	19.0M	19.9M
Other Current Assets	1.2M	1.8M	1.8M	1.9M	1.4M	1.3M
Total Liab	22.1M	11.6M	13.5M	13.4M	9.6M	9.1M
Intangible Assets	266K	125K	83K	62K	33K	31.4K
Property Plant Equipment	921K	725K	2.8M	2.6M	2.3M	3.6M
Short Long Term Debt Total	14.7M	4.7M	7.1M	6.3M	2.4M	2.3M
Property Plant And Equipment Net	921K	472K	2.8M	2.6M	2.5M	3.6M
Current Deferred Revenue	2.6M	6K	3.4M	(589K)	(530.1K)	(503.6K)
Net Debt	(19.5M)	(26.4M)	(53.3M)	(17.9M)	(21.4M)	(22.4M)
Retained Earnings	(411.3M)	(427.0M)	(454.9M)	(483.2M)	(513.2M)	(487.6M)
Non Current Assets Total	1.7M	874K	3.2M	2.6M	2.6M	4.4M
Non Currrent Assets Other	487K	277K	291K	3.0M	3.5M	3.6M
Cash And Short Term Investments	34.1M	31.1M	60.4M	39.2M	23.8M	22.6M
Liabilities And Stockholders Equity	42.1M	37.6M	68.5M	46.7M	30.8M	29.2M
Non Current Liabilities Total	468K	5.2M	8.3M	1.8M	1.1M	1.0M
Other Stockholder Equity	431.3M	453.0M	509.7M	516.5M	534.4M	377.9M
Property Plant And Equipment Gross	921K	472K	7.2M	7.0M	6.8M	6.0M
Total Current Assets	40.4M	36.7M	65.2M	44.1M	28.2M	26.8M
Accumulated Other Comprehensive Income	(134K)	(9.9M)	(4.4M)	(12K)	(1K)	(1.1K)
Short Term Debt	14.6M	4.7M	589K	4.5M	1.3M	1.3M
Net Tangible Assets	19.7M	25.9M	28.9M	33.2M	29.9M	43.5M
Common Stock Total Equity	104K	9K	21K	67K	77.1K	53.0K
Retained Earnings Total Equity	(345.9M)	(392.7M)	(411.3M)	(427.0M)	(384.3M)	(403.6M)
Capital Surpluse	381.1M	386.9M	431.3M	453.0M	521.0M	356.5M
Inventory	4.2M	3.9M	3.3M	3.0K	3.0M	3.2M
Non Current Liabilities Other	0.0	7.1M	468K	1.2M	1.4M	1.9M
Common Stock	21K	67K	146K	17K	20K	19K

Thematic Opportunities

Explore Investment Opportunities

Build portfolios using Macroaxis predefined set of investing ideas. Many of Macroaxis investing ideas can easily outperform a given market. Ideas can also be optimized per your risk profile before portfolio origination is invoked. Macroaxis thematic optimization helps investors identify companies most likely to benefit from changes or shifts in various micro-economic or local macro-level trends. Originating optimal thematic portfolios involves aligning investors' personal views, ideas, and beliefs with their actual investments.

Explore Investing Ideas

Additional Tools for Regulus Stock Analysis

When running Regulus Therapeutics' price analysis, check to measure Regulus Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Regulus Therapeutics is operating at the current time. Most of Regulus Therapeutics' value examination focuses on studying past and present price action to predict the probability of Regulus Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Regulus Therapeutics' price. Additionally, you may evaluate how the addition of Regulus Therapeutics to your portfolios can decrease your overall portfolio volatility.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

Regulus Historical Balance Sheet

Regulus Therapeutics Inventory

3.16 Million

About Regulus Balance Sheet Analysis

Regulus Therapeutics Balance Sheet Chart

Total Assets

Total Current Liabilities

Accounts Payable

Regulus Therapeutics balance sheet Correlations

Regulus Therapeutics Account Relationship Matchups

High Positive Relationship

High Negative Relationship

Regulus Therapeutics balance sheet Accounts

Thematic Opportunities

Explore Investment Opportunities

Additional Tools for Regulus Stock Analysis

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Property Plant And Equipment Net	+ 1.0	Property Plant Equipment
Non Current Assets Total	+ 0.98	Property Plant Equipment
Non Current Assets Total	+ 0.98	Property Plant And Equipment Net
Cash And Short Term Investments	+ 0.97	Total Assets
Short Term Investments	+ 0.95	Total Assets
Cash And Short Term Investments	+ 0.94	Short Term Investments

Net Debt	- 0.98	Cash
Other Stockholder Equity	- 0.93	Retained Earnings
Other Stockholder Equity	- 0.91	Current Deferred Revenue
Other Stockholder Equity	- 0.9	Non Current Liabilities Total
Other Stockholder Equity	- 0.88	Other Liab
Other Stockholder Equity	- 0.81	Total Liab